A phase 3 trial of mepolizumab, an anti-IL-5 biologic, in the treatment of CRSwNP found that, after administration of mepolizumab subcutaneously at a dose of 100 mg every 4 weeks for 52 weeks (in addition to primary care), total endoscopic nasal polyp scores and nasal obstruction VAS scores significantly improved, indicating marked improvement in nasal polyp size and a reduction in polyp recurrence (128). Here, IL5 is linked to polyp.